113 related articles for article (PubMed ID: 22655268)
1. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.
Rettinger E; Meyer V; Kreyenberg H; Volk A; Kuçi S; Willasch A; Koscielniak E; Fulda S; Wels WS; Boenig H; Klingebiel T; Bader P
Front Oncol; 2012; 2():32. PubMed ID: 22655268
[TBL] [Abstract][Full Text] [Related]
2. A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.
Chan WC; Linn YC
Cytotechnology; 2016 Aug; 68(4):735-48. PubMed ID: 25481728
[TBL] [Abstract][Full Text] [Related]
3. Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.
Barth BM; Keasey NR; Wang X; Shanmugavelandy SS; Rampal R; Hricik T; Cabot MC; Kester M; Wang HG; Shultz LD; Tallman MS; Levine RL; Loughran TP; Claxton DF
J Leuk (Los Angel); 2014 Sep; 2(3):. PubMed ID: 28239612
[TBL] [Abstract][Full Text] [Related]
4. Improving cytokine-induced killer cell expansion using a gas-permeable culture method for clinical-scale production.
Tawinwung S; Tudsamran S; Thaiwong R; Asawapanumas T; Wudhikarn K; Chanswangphuwana C; Hirankarn N; Bunworasate U; Suppipat K
Asian Pac J Allergy Immunol; 2023 Jan; ():. PubMed ID: 36592164
[TBL] [Abstract][Full Text] [Related]
5. Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells.
Kim JS; Kim YG; Pyo M; Lee HK; Hong JT; Kim Y; Han SB
Immune Netw; 2015 Apr; 15(2):58-65. PubMed ID: 25922594
[TBL] [Abstract][Full Text] [Related]
6. SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.
Rettinger E; Glatthaar A; Abhari BA; Oelsner S; Pfirrmann V; Huenecke S; Kuçi S; Kreyenberg H; Willasch AM; Klingebiel T; Fulda S; Bader P
Front Pediatr; 2014; 2():75. PubMed ID: 25101252
[TBL] [Abstract][Full Text] [Related]
7. Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation.
Ishikawa F
Int J Hematol; 2013 Dec; 98(6):634-40. PubMed ID: 24258713
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
9. Humanized mice for immune system investigation: progress, promise and challenges.
Shultz LD; Brehm MA; Garcia-Martinez JV; Greiner DL
Nat Rev Immunol; 2012 Nov; 12(11):786-98. PubMed ID: 23059428
[TBL] [Abstract][Full Text] [Related]
10. [Construction and Identification of Acute Myeloid Leukemia NOD/SCID Mouse Model by Tail Vein Injection of THP-1 Cells].
Liao XM; Chen Q; Feng ZX; Yang XM; Zhu CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):424-429. PubMed ID: 32319373
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J; Niu T
J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
[TBL] [Abstract][Full Text] [Related]
12. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
13. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
14. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
Sabry M; Lowdell MW
Stem Cells Transl Med; 2020 Sep; 9(9):974-984. PubMed ID: 32416056
[TBL] [Abstract][Full Text] [Related]
15. Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience.
Merker M; Meister MT; Heinze A; Jarisch A; Sörensen J; Huenecke S; Bremm M; Cappel C; Klingebiel T; Bader P; Rettinger E
Oncotarget; 2019 Oct; 10(58):6138-6151. PubMed ID: 31692914
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
17. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Wu Z; Cheung NV
Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.
Peinemann F; Enk H; Smith LA
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008216. PubMed ID: 28407197
[TBL] [Abstract][Full Text] [Related]
19. NaHCO
Yuan YH; Zhou CF; Yuan J; Liu L; Guo XR; Wang XL; Ding Y; Wang XN; Li DS; Tu HJ
Oncol Lett; 2016 Nov; 12(5):3167-3174. PubMed ID: 27899977
[TBL] [Abstract][Full Text] [Related]
20. In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.
Bremm M; Huenecke S; Zimmermann O; Pfirrmann V; Quaiser A; Bonig H; Soerensen J; Klingebiel T; Rettinger E; Bader P; Cappel C
J Transl Med; 2016 Sep; 14(1):264. PubMed ID: 27620209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
